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Background: Protein synthesis is tightly regulated and alterations to translation are characteristic of many cancers.
Translation regulation is largely exerted at initiation through the eukaryotic translation initiation factor 4 F (eIF4F).
eIF4F is pivotal for oncogenic signaling as it integrates mitogenic signals to amplify production of pro-growth and
pro-survival factors. Convergence of these signals on eIF4F positions this factor as a gatekeeper of malignant fate.
While the oncogenic properties of eIF4F have been characterized, genome-wide evaluation of eIF4F translational
output is incomplete yet critical for developing novel translation-targeted therapies.
Results: To understand the impact of eIF4F on malignancy, we utilized a genome-wide ribosome profiling approach
to identify eIF4F-driven mRNAs in MDA-MB-231 breast cancer cells. Using Silvestrol, a selective eIF4A inhibitor,
we identify 284 genes that rely on eIF4A for efficient translation. Our screen confirmed several known eIF4F-dependent
genes and identified many unrecognized targets of translation regulation. We show that 5′UTR complexity determines
Silvestrol-sensitivity and altering 5′UTR structure modifies translational output. We highlight physiological implications
of eIF4A inhibition, providing mechanistic insight into eIF4F pro-oncogenic activity.
Conclusions: Here we describe the transcriptome-wide consequence of eIF4A inhibition in malignant cells, define
mRNA features that confer eIF4A dependence, and provide genetic support for Silvestrol’s anti-oncogenic properties.
Importantly, our results show that eIF4A inhibition alters translation of an mRNA subset distinct from those affected by
mTOR-mediated eIF4E inhibition. These results have significant implications for therapeutically targeting translation and
underscore a dynamic role for eIF4F in remodeling the proteome toward malignancy.Background
Energetically, protein synthesis is the most costly step
on the path toward gene expression and is thus a rigidly
controlled process. In eukaryotes, protein synthesis occurs
in three phases: translation initiation, elongation and
termination. Although translation is controlled at multiple
stages, regulation is primarily exerted at initiation, the
phase in which 80S ribosomes assemble onto mRNA tran-
scripts. Regulation of initiation is mediated by multiple
factors, many of which converge on the assembly of the
eukaryotic initiation factor 4F (eIF4F). This heterotrimeric
complex is composed of eIF4E, the rate-limiting protein
which binds the 5′-7-methylguanosine cap on cellular* Correspondence: claudia.rubio@novartis.com
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unless otherwise stated.mRNA transcripts; eIF4A, a DEAD-box RNA helicase;
and eIF4G, a scaffolding protein which bridges eIF4E and
eIF4A, and recruits eIF3 and the 43S pre-initiation com-
plex. Formation of eIF4F is tightly controlled by multiple
mitogenic signaling pathways, namely mitogen-activated
protein kinase (MAPK) and phosphoinositide-3-kinase
(PI3K)/Akt/mammalian target of rapamycin (mTOR), and
has been shown to stimulate translation of mRNAs in-
volved in cell proliferation, growth, survival, cell cycle
progression, and DNA damage repair [1-3]. Moreover,
components of the translation apparatus and the rate
of protein synthesis are commonly increased in cancer
[4,5], overexpression of translation initiation factors, in
particular eIF4E and eIF4G, is transforming [6,7], and
increased levels of PDCD4, a negative regulator of
eIF4A, suppresses transformation [8,9]. Thus, eIF4F hastd. This is an Open Access article distributed under the terms of the Creative
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mechanism by which increased eIF4F activity can cause
transformation remains unclear. Likewise, the particular
mechanisms by which different components of eIF4F in-
duce malignancy are not well understood. Nevertheless,
eIF4F is a point of convergence for parallel signaling
pathways and the complex plays a pivotal role in cancer
by integrating aberrant oncogenic signals and amplify-
ing a translational output that can steer the cell toward
malignancy.
Significant progress has been made toward understand-
ing the machinery that drives protein synthesis. However,
the underlying mechanisms by which individual eIF4F
components contribute to translation regulation in the
cell remain ambiguous. Emerging methods that allow
for global dissection of translation have bolstered the
long standing knowledge that translation is subject to
considerable regulation and thus plays a key role in
regulating gene expression [10-13]. Studies suggest
that translation machinery may discriminate between
particular mRNA transcripts [14-16] yet the features that
might impart individual transcripts with a competitive ad-
vantage for eIF4F have not been clearly elucidated. One
feature that likely influences the efficiency of translation is
the secondary structure of 5′ UTRs. Indeed, engineered 5′
UTR secondary structures have been shown to negatively
impact translation efficiency using synthetic reporter
constructs [14,17]. Furthermore, eIF4F is required for
unwinding 5′ UTR structure on certain mRNAs [18,19]
and the degree of structure is proportional to the require-
ment for eIF4A RNA helicase activity in vitro [20]. These
data commonly lead to the hypothesis that cellular mRNAs
with complex 5′ UTRs must depend more heavily on the
eIF4F complex for efficient translation.
eIF4A is an integral part of the heterotrimeric eIF4F
complex and the only component with known enzymatic
activity. While several eIF4A-regulated genes have been
identified, in-depth studies have yet to provide a genome-
wide description of the eIF4A target gene landscape. We
sought to comprehensively define the cellular mRNAs
regulated by eIF4A and investigate the mRNA features
that confer dependence on this helicase by directly block-
ing its activity. To achieve this, we employed the potent
and specific eIF4A inhibitor Silvestrol. This compound
has been shown to selectively target the RNA helicase ac-
tivity of eIF4A both in vitro and in vivo, thereby impairing
translation initiation [21,22], and is known to have robust
anti-cancer effects [23,24]. Moreover, Silvestrol prefer-
entially inhibits translation of several weakly initiating
mRNAs and its anti-oncogenic effects have been proposed
to act through favored inhibition of malignancy-related
mRNAs [23]. Here we use Silvestrol as a tool to dissect
the translational output of eIF4A, define the features
that bestow transcripts with a competitive advantagefor eIF4A, and elucidate the mechanisms underlying
the pro-oncogenic activity of eIF4F.
Results
As a model, we selected the triple-negative breast can-
cer cell line MDA-MB-231 for its known sensitivity to
Silvestrol [23]. This allowed for careful optimization of
the concentration and duration of compound treatment
and provided a context in which to evaluate the contri-
bution of eIF4A-dependent translation to malignancy.
Exposure of MDA-MB-231 cells to increasing concen-
trations of Silvestrol impaired cell survival (Figure 1a)
while the compound had minimal effects on survival of
non-malignant MCF-10A cells (Figure 1b). Likewise, the
effect of Silvestrol on global translation was measured
by monitoring 35S-methionine incorporation into newly
synthesized proteins. To mitigate off-target or secondary
effects of drug treatment, we chose to treat cells with a
low concentration of Silvestrol for a short time period.
We selected a concentration of 25 nM Silvestrol, which
had negligible effects on global translation after 2 hours of
exposure (Figure 1c). To further evaluate the effect of
eIF4A inhibition on the translation apparatus, we analyzed
the polysome profiles of MDA-MB-231 cells left untreated
or treated with 25 nM Silvestrol for 2 hours. Silvestrol
treatment liberated 40S and 60S ribosomal subunits,
dramatically increased the abundance of 80S monosomes
and had minimal effects on the abundance of polysomes
(Figure 1d). In contrast, treatment with harringtonine,
which globally arrests ribosomes at initiation codons,
caused an accumulation of ribosomal subunits and 80S
monosomes and eliminated polysomes (Additional file 1).
Taken together, these results suggested that Silvestrol
blocked the translation of a subset of mRNA transcripts at
initiation. To explore the possibility that a select mRNA
subset is regulated by eIF4A, we employed the compre-
hensive, transcriptome-wide method of ribosome profiling
[10-13,15,16]. This approach allows for the detailed ana-
lysis of transcriptome utilization by translation machinery
through the use of next-generation sequencing to quantify
ribosome-protected mRNA fragments (ribosome footprints
(RFs)). MDA-MB-231 cells were treated with vehicle
(DMSO) or 25 nM Silvestrol and cell lysates, collected
at 1 and 2 hours after treatment, were RNase-digested
and fractionated to collect monosomes. Mass spectrom-
etry analysis of monosome fractions used for ribosome
profiling revealed that the majority of peptides present
were derived from ribosomal components in both
DMSO- and Silvestrol-treated lysates, indicating that
protected mRNAs isolated by our method were engaged
by ribosomes (Table S1 in Additional file 2). Likewise,
the average length of sequenced fragments in all sam-
ples was approximately 32 nucleotides, the expected
size of a ribosome-protected mRNA fragment (Figure S2a
Figure 1 eIF4A inhibition reveals genes under translational control in MDA-MB-231 cells. (a) MDA-MB-231 breast cancer cells or (b) MCF-10A
non-malignant luminal breast cells were treated with increasing concentrations of Silvestrol for 72 hours. Cell proliferation was measured by lysing in
Cell Titer Glow reagent and measuring luminescence in relative light units (RLU EC50 MDA-MB-231 = 6 nM; EC50 MCF-10A >3 μM. (c) MDA-MB-231 cells
were treated with DMSO or 25 nM Silvestrol, pulsed with 35S-methionine for 15 minutes prior to harvest and harvested at 0, 1 or 2 hours after
treatment. Bar graph represents counts per minute (CPM) normalized to total protein. Error bars represent standard error (n = 3). (d) Polysome
profiles of MDA-MB-231 cells treated with DMSO (top panel; 21% ribosomal subunits and 80S monosomes, 79% polysomes; n =2) or with 25 nM
Silvestrol (bottom panel; 75% ribosomal subunits and 80S monosomes, 25% polysomes; n =2) for 2 hours. A260, the absorbance of light at 260 nm.
(e) Distribution of ribosome footprint (RF) RPKM values from DMSO-treated MDA-MB-231 cells (mean Log2 RPKM value =4.78) compared with
Silvestrol-treated cells (mean Log2 RPKM value =4.49). RPKM = reads per kilobase per million. (f) Scatter plot of RF densities (measured in RPKM)
in cells treated with 25 nM Silvestrol versus DMSO for 1 or 2 hours. Silvestrol-sensitive genes are indicated in dark blue. Correlation coefficients
for biological replicates (n =2) are DMSO r =0.945 and Silvestrol r =0.977. (g) Distribution of changes in translation efficiency (TE) between
DMSO- or Silvestrol-treated cells. To calculate TE, RPKM values from RF RNAs were normalized to RPKM values from mRNA sequencing results
generated from identical biological samples. Silvestrol-sensitive genes with decreased TE (z-score below -1.5) and Silvestrol-resistant genes (z-score
>1.5) are indicated. Population mean indicated by a solid vertical line; dotted vertical lines indicate σ values above and below the mean.
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million reads that mapped to a total of 17,703 annotated
mRNA transcripts (Figure S2b in Additional file 3). Of
these, 8,393 genes were sufficiently represented in oursequencing data to provide reliable measurements of their
translational status. Sequencing data were quantified by
calculating the reads per kilobase per million (RPKM)
value for each gene. The RPKM values generated from
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the extent to which a given transcript is engaged by
ribosomes [10]. Comparison of RF data from DMSO-
and Silvestrol-treated cells revealed that genome-wide
translation was not significantly reduced after exposure to
compound for 2 hours (Figure 1e). To identify genes that
depend on eIF4A for robust translation, the translation
efficiency (TE) value of each transcript was calculated. TE
values are generated by dividing RPKM values from RF
data by RPKM values from mRNA-seq data, thereby nor-
malizing translation to steady-state transcript abundance.
The TE value thereby provides a quantitative measure of
transcript-specific utilization by translation machinery and
uncouples changes in transcription from changes due to
translation regulation. We calculated the fold change in
TE (ΔTE) due to eIF4A inhibition by dividing TE values
from Silvestrol-treated cells by those from DMSO-treated
cells; thus, ΔTE = TESilvestrol/TEDMSO for each gene. Of
the 8,393 genes whose translation was robustly measured,
we identified 284 genes that showed markedly reduced
translation as a result of eIF4A inhibition (z-score
below -1.5; Table S2 in Additional file 2) and 146 genes
that showed increased translation upon eIF4A inhib-
ition (z-score above 1.5; Table S3 in Additional file 2)
(Figure 1f-g; Figure S2c in Additional file 3).
To validate the observation that Silvestrol reduces
translation of these genes, we monitored the polysome
association of specific mRNAs. Polysomes from MDA-
MB-231 cells treated with 25 nM Silvestrol or vehicle
were fractionated by sucrose gradient and the resulting
fractions were analyzed by quantitative RT-PCR for
CyclinD1, ARF6, BCL2, ROCK1, CDK6, and β-actin
Consistent with our ribosome profiling data, significant
shifts in polysomes were observed for CyclinD1, ARF6,
BCL2, ROCK1, and CDK6, but not for β-actin (Additional
file 4). These data confirm that TE values obtained by
ribosome profiling are consistent with changes in ribo-
some occupation on specific transcripts.
The translation initiation complex eIF4F has been shown
to regulate genes with exogenous structural elements added
to their 5′ UTRs [14,17-19]. Since Silvestrol inhibits the
RNA helicase component of eIF4F, we surmised that the 5′
ends of Silvestrol-sensitive genes would be more structured
than genes insensitive to Silvestrol. Using CONTRAfold, a
statistical learning structure prediction algorithm [25], we
evaluated the secondary structure of 5′ UTRs derived
from the 284 mRNAs that showed reduced translation
upon Silvestrol treatment. To control for this analysis,
we analyzed 5′ UTRs from Silvestrol-insensitive genes
(n =6303) in parallel with those from the 284 Silvestrol-
sensitive genes. We found that the pool of 5′ UTRs
from Silvestrol-sensitive genes was enriched with struc-
tured elements when compared to the control pool. 5′
UTRs from mRNAs with z-scores below -1.5 had morenegative free energy values than those with z-scores
above -1.5 (Figure 2a; Figure S4a in Additional file 5).
The difference in free energy values between genes with
decreased TE in Silvestrol and insensitive genes was
highly significant (P =2.53 × 10-67) and a difference in
distribution of ΔG values from genes with increased
TE was also notable compared with the insensitive pool
(P =4.25 × 10-7) (Figure 2a). Evaluation of 5′ UTRs for
length and percentage GC content revealed that mRNAs
with decreased TE had markedly longer 5′ UTRs than
those from insensitive genes (P =1.39 × 10-133) while those
from genes with increased TE were comparatively shorter
(P =4.82 × 10-10; Figure 2b). Likewise, the overall per-
centage GC content was significantly lower in the 5′
UTRs of mRNAs with decreased TE (P =1.02 × 10-47)
and slightly higher in those from genes with increased
TE (P =8.08 × 10-6) (Figure 2c). These data suggest that
eIF4A-dependent genes have a 5′ UTR signature char-
acterized by long, structured sequences with relatively
low overall GC content.
To evaluate the contribution of gene-specific 5′ UTRs
to eIF4A-dependence we created reporter constructs
bearing select 5′ UTRs derived from our analyses. We
made use of the short-lived luciferase reporter, luc2CP,
which contains two protein-destabilizing sequences, hCL1
and hPEST, that reduce the half-life of luciferase to ap-
proximately 30 minutes (Figure S4b in Additional file 5).
This allowed us to uncouple the contribution of protein
stability to our measurement and monitor Silvestrol-
sensitive changes in translation on a short time scale.
We placed the luc2CP gene under control of the CMV
promoter and fused the luc2CP open reading frame to
the 5′ UTR sequences from three Silvestrol-sensitive
genes, CyclinD1, ARF6 and ROCK1, and one Silvestrol-
insensitive gene, PFN2 (Figure 2e; FigureS4c-e in Additional
file 5). These constructs were stably expressed in 293T
cells and evaluated for sensitivity to Silvestrol by meas-
uring luciferase activity in the presence of increasing
amounts of Silvestrol after 40 minutes of exposure to
compound. Reporter constructs bearing highly struc-
tured 5′ UTRs, from ARF6 (ΔG = -264.5 kcal/mol) and
ROCK1 (ΔG = -313 kcal/mol), were significantly more
sensitive to Silvestrol than unstructured controls, CMV
alone and PFN2 (ΔG = -115.57 kcal/mol) (Figure 2f;
Table S4 in Additional file 2). These differences were
directly attributable to changes in translation since
mRNA levels were unaffected by the presence of
Silvestrol (Figure S4f in Additional file 5). In addition,
treatment with hippuristanol, a second inhibitor of
eIF4A, produced similar results in our reporter assay
(Additional file 6). Notably, the relatively unstructured
5′ UTR of CyclinD1 (ΔG = -47 kcal/mol) (Figure S6a,b
in Additional file 7) had little impact on the sensitivity
of our reporter to eIF4A inhibition.
Figure 2 Silvestrol-sensitive mRNAs are enriched with complex 5′ UTRs. (a) Box plot showing distribution of free energy values for 5′
UTRs of Silvestrol-sensitive genes (Decreased, n =284, z-score below -1.5), genes increased in Silvestrol (n =146 genes, z-score >1.5), and
genes insensitive to Silvestrol (n =6,303). ***P =2.53 × 10-67, **P =1.097 × 10-27 and *P =4.25 × 10-7. Energy values were predicted using the
CONTRAfold algorithm [25]. (b) Box plot showing distribution of 5′ UTR length, L: ***P =1.39 × 10-133, **P =3.1 × 10-44 and *P =4.83 × 10-10.
(c) Box plot showing distribution of GC content: ***P =1.02 × 10-47, **P =3.35 × 10-23 and *P =8.08 × 10-6. For genes with decreased TE:
n =284, ΔGmean = -103.9 kcal/mol, Lmean =493.4 nucleotides, GCmean =59.8%. For insensitive genes: n =6,303, ΔGmean = -54.72 kcal/mol, Lmean =223.6
nucleotides, GCmean =66.9%. For genes with increased TE: n =142, ΔGmean = -45.93 kcal/mol, Lmean =171.8 nucleotides, GCmean =71.23%. Significance
values were determined using the two-tailed Mann-Whitney U test (d) RPKM and TE values from ribosome profiling data for genes used in 5′
UTR analyses of CyclinD1, ARF6, ROCK1 and PFN2. (e) Luciferase reporter constructs, stably transfected into 293 T cells, were treated with
increasing concentrations of Silvestrol and luciferase expression was measured after 40 minutes; constructs bearing 5′ UTRs from Silvestrol-sensitive
genes (CyclinD1, ROCK1, ARF6) or insensitive genes (PFN2 or CMV alone) were compared. Triplicate values were obtained in each experiment; data
presented were obtained from four independent experiments. (f) Luciferase reporter expression in stably transfected 293 T cells treated with
increasing concentrations of Silvestrol; constructs bearing ARF6wt 5′ UTR or ARF6mut 5′ UTR were compared; data presented were obtained
from two independent experiments with measurements taken in triplicate.
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Silvestrol-sensitivity of our reporter, we sought to disrupt
structured regions within the 5′ UTR of ARF6. To thisend, we predicted regions of structure by determining the
ΔG value of 20-nucleotide fragments across the length of
the ARF6 5′ UTR. The resulting ΔG values were plotted
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structure (Figure S6c in Additional file 7). Evaluation
of the percentage GC content across the length of the
5′ UTR revealed that localized structures in the 5′
UTR correlated well with clusters of high GC content
(Figure S6d in Additional file 7). Based on these predictive
analyses, a series of single nucleotide changes were made
to the ARF6 5′ UTR to remove base-pairing interactions
in structured regions. Additionally, a long-range base-
pairing interaction expected to obscure the ARF6 trans-
lation start codon was disrupted by mutagenesis. The
resulting 5′ UTR, termed ARF6mut, was identical in length
and overall GC content but its localized structures and
GC-rich peaks were removed or reduced (Figure S6e-f
in Additional file 7; see the mutated residues in the
'Oligonucleotide' section in Materials and methods).
The ARF6mut 5′ UTR had an increased ΔG value
of -142.4 kcal/mol (compared with the wild-type
ΔGARF6 5′ UTR of -264.5 kcal/mol). The introduction
of ARF6mut into our luc2CP reporter decreased the
sensitivity of our reporter construct to Silvestrol (Figure 2f),
indicating that reducing structure in the 5′ UTR of ARF6
decreased eIF4A-dependency of the reporter. Taken
together, these data demonstrate that structured regions
in the 5′ UTR of Silvestrol-sensitive ARF6 mRNA confer
dependence on eIF4A for translation initiation and that
the degree of structure correlates with increased sensitivity
to eIF4A inhibition.
Gene ontology (GO) analysis of Silvestrol-sensitive
genes revealed that a large proportion of eIF4A-
dependent genes were involved in cell cycle progression
(P =7.37 × 10-7; Figure 3a). Since the cell cycle is often
misregulated in cancer, we explored the biological conse-
quence of Silvestrol treatment by examining the impact of
eIF4A inhibition on cell cycle progression. Asynchronous
MDA-MB-231 cells were treated with Silvestrol and
the cell cycle was monitored by bromodeoxyuridine
(BrDU) incorporation and propidium iodide (PI) stain-
ing followed by flow cytometry. Silvestrol treatment
prevented MDA-MB-231 cells from entering S phase
and caused accumulation in the G2 phase of the cell
cycle (Figure 3b). To further explore the block to S
phase transition, we investigated the effect of Silvestrol in
synchronized cells. MDA-MB-231 cells were arrested in
early G1 by serum starvation, then released from starva-
tion by the addition of serum-containing medium in the
presence or absence of Silvestrol and cell cycle progres-
sion was monitored over time. Upon release from serum
starvation, cells accumulated in G1 phase, which coin-
cided with a robust block to S phase entry in the presence
of Silvestrol. This block was accompanied by a significant
increase in sub-G1 cells, indicating the onset of cell death
during prolonged drug treatment (Figure 3c, bottom
panels). Indeed, GO analysis of our ribosome profilingdata predicted that Silvestrol treatment would impair
cell survival (P =1.12 × 10-3; Figure 3a). In this assay,
we also observed that cells remaining in S phase after
serum starvation were able to enter G2, indicated by a
rise in the percentage of G2 cells 24 hours after release
in the presence of Silvestrol (Figure 3c, bottom panels).
Thus, Silvestrol prevented cells from entering S phase
but not G2.
Based on our ribosome profiling data, we identified
eIF4A-regulated genes that act at the G1/S phase transi-
tion. In particular, the translation but not transcription
of Cyclin D1, Cyclin D2 and CDK6 was sensitive to
Silvestrol treatment (Figure 3g). Upon Silvestrol treatment,
we observed a rapid loss of Cyclin D1 protein but no loss
of Cyclin E1 or Cyclin B1 protein (Figure 3d). Likewise,
we observed a significant, Silvestrol-mediated loss of the
anti-apoptotic factor Bcl2 (Figure 3e), attributable to a
block in BCL2 translation rather than transcription
(Figure 3g). Loss of Bcl2 protein was accompanied by
cleavage of PARP (Figure 3f) and occurred concomitantly
with the observed increase in sub-G1 cells (Figure 3c). To-
gether, these data suggest that inhibition of eIF4A in
MDA-MB-231 cells primarily blocks cell cycle progression
at the G1/S phase transition, likely through loss of Cyclin
D1, Cyclin D2 and Cdk6, and induces apoptosis, in part,
by inhibiting translation of BCL2.
Besides targeting genes important for cell cycle pro-
gression and survival, our data indicated that Silvestrol
had a significant effect on genes involved in cell migra-
tion (P =1.13 × 10-3; Figure 3a). Indeed, inhibition of
eIF4F was recently shown to impair migration of highly
metastatic cancers [26]. To explore this further, we
measured the migration of MDA-MB-231 cells in a
trans-well migration assay. In this assay, cell migration was
inhibited at low concentrations of Silvestrol (Figure S7a in
Additional file 8) and decreased in a dose-dependent man-
ner. Furthermore, a scratch wound assay showed a block to
wound closure in the presence of Silvestrol (Figure S7b,c in
Additional file 8). Among the genes we identified as
Silvestrol-sensitive, ARF6 is a master regulator of cell
migration in MDA-MB-231 cells [27,28]. In our study,
inhibition of cell migration was accompanied by a loss
of Arf6 protein in a time-dependent manner similar to
the impairment of migration (Figure S7d in Additional
file 8).
Recently, an in-depth investigation into the genome-
wide program of mTOR-regulated genes identified a
subset of growth-related mRNAs regulated by eIF4E via
the 4E-binding proteins 4E-BP1/2. This pool of mRNAs
was overwhelmingly characterized by the presence of
5′ TOP and 5′ TOP-like sequences adjacent to the
5′-m7GTP cap and lacked mRNAs with long, structured
5′ UTRs [15,16]. Unexpectedly, we found that the popula-
tion of eIF4A-dependent mRNAs did not carry 5′ UTRs
Figure 3 (See legend on next page.)
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Figure 3 eIF4A regulates cell cycle progression and apoptosis. (a) Gene ontology (GO) analysis predictions of the effects of Silvestrol on
cancer-related pathways in MDA-MB-231 cells. (b) Cell cycle progression of MDA-MB-231 cells was monitored after treatment with DMSO (left) or
Silvestrol (right) for 24 hours. Cells were pulsed with bromodeoxyuridine (BrDU) for 30 minutes prior to harvest. Upon harvest, cells were fixed,
stained with anti-BrDU-fluorescein isothiocyanate (FITC) antibody and propidium iodide (PI) and analyzed by fluorescence-activated cell sorting
(FACS) (c) MDA-MB-231 cells were synchronized by serum starvation for 24 hours then released from starvation in the presence of DMSO (top
panels) or Silvestrol (bottom panels). The cell cycle was monitored over time by BrDU incorporation and PI staining as in Figure 3a. (d) MDA-MB-231
cells were treated with DMSO or Silvestrol for 0, 2 or 6 hours prior to lysis. Lysates were analyzed by Western blotting for proteins indicated.
(e,f) MDA-MB-231 cells were treated with DMSO or Silvestrol from 0, 8, 16 and 24 hours prior to lysis; lysates were analyzed by Western
blotting for indicated proteins. (g) Tables showing RPKM values from ribosome profiling data for genes implicated in cell cycle progression
(top) and apoptosis (bottom).
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by long, complex 5′ UTRs containing significant structure
and an increased prevalence of 5′ UTR sequences with
alternative transcription start sites (TSSs) or 5′ UTR
introns. We collectively term these ‘variant 5′ UTRs’
(Figure 4a). Taken together, these data suggest that
diminishing eIF4F assembly through 4E-BP1/2 is not
equivalent to direct abrogation of eIF4A helicase activity.
These intriguing observations imply that the subset of
eIF4A-dependent mRNAs is distinct from those which
rely on efficient eIF4F assembly for translation. To explore
this idea, we selected two cell lines, MDA-MB-231 and
PC-3 prostate cancer cells, for their known sensitivity to
inhibition of either eIF4A or mTOR. We first treated
MDA-MB-231 or PC-3 cells with DMSO, Silvestrol or
INK128, a catalytic mTOR inhibitor, and analyzed lysates
by Western blot for two eIF4A-sensitive proteins, Cyclin
D1 and Arf6. We found that neither Arf6 nor Cyclin D1
protein production was affected by INK128 treatment of
MDA-MB-231 (Figure S8a in Additional file 9) or PC-3
cells (Figure S8b in Additional file 9). This clue that eIF4A
and mTOR/4E-BPs differentially affect translation lead us
to hypothesize that catalytic inhibition of mTOR in com-
bination with Silvestrol would have additive rather than
synergistic or epistatic activity compared with Silvestrol
alone. To test this, cells were treated with Silvestrol in
combination with one of two catalytic mTOR inhibitors,
PP242 or INK128 [15], and survival was measured
72 hours after exposure. The inclusion of INK128 had
an additive effect on cell survival compared with treat-
ment with Silvestrol alone in both cell lines (Figure 4b,c;
Figure S9a,b in Additional file 10). Likewise, treatment
with PP242 was additive in combination with Silvestrol
as further inhibition of survival in both cell types was
observed even at very low concentrations of compound
(Figure S9c-f in Additional file 10). Dose-matrix plots of
these data (lower panels of Figure S9a,b,e,f in Additional
file 10) are best described by a highest single agent- or
Bliss-like masking model in which dual inhibition of
targets across two intersecting pathways is required for
full inhibition [29].
To evaluate whether mTOR inhibition specifically
reduces the translation of a different mRNA subsetfrom that regulated by eIF4A, we performed ribosome
profiling of MDA-MB-231 cells treated with INK128.
We identified 244 transcripts that showed reduced TE
in the presence of INK128 (Figure 4d). This pool of
mTOR-dependent genes shared only one member in
common with those showing decreased TE in the pres-
ence of Silvestrol and was identical to the pool of genes
identified as mTOR-dependent by Hsieh et al. [15] and
Thoreen et al. [16] (Table S6 in Additional file 2).
Moreover, INK128-sensitive transcripts were predom-
inantly composed of known 5′ TOP mRNAs (Figure 4e)
as well as transcripts bearing 5′ TOP-like sequences
[16,30] and largely unstructured 5′ UTRs (Figure 4f ).
Notably, we found that variant 5′ UTRs occurred in
INK128-dependent mRNAs at nearly the same frequency
as in those showing decreased TE in Silvestrol (Figure 4f,
compared with Figure 4a), though none of these genes
were common to both pools (Table S6 in Additional
file 2). Indeed, the TE of INK128-sensitive genes was
not reduced in Silvestrol-treated cells, nor did Silvestrol-
sensitive genes show reduced TE upon INK128 treatment
(Figure 4g). Taken together, these data support a model in
which the pool of mRNAs that are regulated through the
assembly of eIF4E with eIF4F components is discrete from
the mRNA subset that depends on eIF4A activity for effi-
cient translation (Figure 4h).
Discussion
Here we confirm and refine the long-standing hypothesis
that the eIF4F heterotrimer selectively regulates the
translation of mRNAs with long, structured 5′ UTRs
and provide a genome-wide account of genes that rely
on eIF4A activity for translation. Previous studies have
shown that structured RNA elements derived from ex-
ogenous sources increased dependency on eIF4F when
added to 5′ UTR reporters [14,17-20]. However, our
work provides the first evidence that this principal is
upheld in the context of the entire transcriptome and
the first demonstration that structured 5′ UTRs derived
directly from cellular transcripts confer dependence on
eIF4A for efficient translation.
While our data confirm that structured 5′ UTRs require
eIF4A activity, this work indicates that the length and
Figure 4 (See legend on next page.)
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Figure 4 eIF4A regulates the TE of a discrete mRNA subset with common features. (a) 5′ UTR sequences from Silvestrol-responsive genes
were analyzed for secondary structure, variant 5′ UTRs and 5′ TOP sequences. Complex 5′ UTRs are defined as those with significant secondary
structure (ΔG < -104 kcal/mol) or annotated 5′ UTR variants. Genes with decreased TE: 37.3% structured, 38.2% variant, 2.3% 5′ TOP or 5′ TOP-like,
24.7% non-TOP and non-complex. Insensitive TE genes: 8.3% structured, 0.3% variant, 3.7% 5′ TOP or 5′ TOP-like, 88% non-TOP and non-complex.
Genes with increased TE: 10.6% structured, 0% variant, 2.1% 5′ TOP or 5′ TOP-like, 87.2% non-TOP and non-complex. (b,c) PC-3 (b) or MDA-MB-231 (c)
cells were treated with increasing concentrations of Silvestrol in combination with INK128 at fixed doses: 15.6 nM, 31.25 nM and 62.5 nM. Cell viability
was measured by CellTiter-Glo after 3 days. (d) Distribution of changes in TE upon INK128 treatment of MDA-MB-231 cells. INK128-sensitive genes with
decreased TE (z-score < -1.5) are indicated. Population mean indicated by a solid vertical line; dotted vertical lines indicate σ values above
and below the mean. (e) z-scores for INK128-dependent changes in TE for known 5′ TOP mRNAs. The dotted line is drawn at z-score = -1.5.
(f) 5′ UTR characteristics for genes with INK128-dependent reduction in TE; 51.2% 5′ TOP or 5′ TOP-like, 37.3% variant, 7.7% structured and
6.6% non-TOP and non-complex. (g) z-scores of transcripts in INK128-treated (left panel) or Silvestrol-treated (right panel) MDA-MB-231 cells.
Each point represents a single gene; genes in orange had decreased TE in INK128 while those in blue had decreased TE in Silvestrol. Dotted
lines are drawn at z-score = -1.5. (h) A model proposing that the subset of mRNAs most sensitive to eIF4A inhibition is distinct from the pool
of mRNAs regulated via mTOR-mediated assembly of eIF4E and eIF4G.
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confer eIF4A dependence. In addition to increased sec-
ondary structure and length, we observed that 38.16%
of Silvestrol-sensitive genes have the capacity to encode
multiple 5′ UTR variants while only 0.3% of insensitive
genes carry a variant 5′ UTR (Figure 4a; Table S4 in
Additional file 2). These variants are characterized by
the presence of alternative TSSs or 5′ UTR introns that
are not prevalent in Silvestrol-insensitive genes. This
unforeseen observation suggests that modification of
the 5′ UTR, resulting from the use of alternative TSSs
or alternative splicing events, could convey different
modes of translational control on otherwise similar
mRNA transcripts. One attractive hypothesis is that
alternative splicing of 5′ UTR sequences facilitates transla-
tion of spliced mRNAs through recruitment of eIF4A3. In
support of this, evidence suggests that the role of eIF4A3
in translation includes the ATP-dependent rearrangement
of protein-protein or protein-mRNA complexes since this
nuclear isoform of eIF4A binds mRNAs at exon junctions
[31-33]. Understanding how and when alternative TSSs or
splicing events are used to generate 5′ UTR variants and
exploring the mechanisms by which such variants are reg-
ulated by the translation machinery are intriguing avenues
for future investigation.
The observation that translation of CyclinD1, which
bears a relatively short, unstructured 5′ UTR, was strongly
regulated in an eIF4A-dependent manner was un-
anticipated. Indeed, eIF4A has been shown to enhance
pre-initiation complex scanning even on mRNAs with
unstructured 5′ UTRs [19]. Consistent with this, we
observed that the less-structured 5′ UTR of CyclinD1
is unable to impart Silvestrol-sensitivity to our reporter
yet the translation of CyclinD1 itself is sensitive to
eIF4A inhibition (Figure 3c). These observations sug-
gest that some determinants of eIF4A dependence,
which govern the translation of CyclinD1 and possibly
other transcripts with unstructured 5′ UTRs, have yet
to be discovered. Alternatively, the observed decreasein CyclinD1 translation could be the result of an indirect
effect, whereby the translation of a regulatory factor
governing CyclinD1 is itself modulated by Silvestrol.
While this manuscript was under revision, a similar
study using Silvestrol in T-cell acute lymphoblastic
leukemia was published by Wolfe et al. [34]. The results
of this study agree with our findings that eIF4A regu-
lates transcripts with long, structured 5′ UTRs and
show that an additional 9- or 12-nucleotide guanine
quartet, (CGG)4, marks eIF4A-dependent transcripts. In
our study, approximately 25% of 5′ UTRs from genes
with reduced TE in MDA-MB-231 cells contain this
repeat. Notably, an intact (CGG)4 motif is present in
both the ARF6 and ARF6mut 5′ UTR reporter constructs
(see Materials and methods), which display differential
sensitivities to eIF4A inhibition. Thus, additional 5′ UTR
structural features contribute significantly to eIF4A-
mediated translation. While the guanine quartet marks
a subset of eIF4A-dependent transcripts, our data indi-
cate that the presence of a (CGG)4 motif in the 5′ UTR
is not a sole determinant of eIF4A dependence.
Finally, we observed that many 5′ UTRs from Silvestrol-
insensitive mRNAs have extremely low ΔG values and
some of these values overlap with those of Silvestrol-
sensitive genes. One possible explanation is that helicases
with a redundant function in translation, such as DHX29,
might serve to unwind highly structured mRNAs when
eIF4A activity is compromised [35].
In addition to describing mRNA features that contribute
to eIF4A dependence, transcriptome-wide ribosome pro-
filing of Silvestrol-treated cells provided genetic insight
into the physiological consequences of eIF4A inhibition.
Silvestrol-related compounds have been suggested to
block progression through the cell cycle [36] yet the
genetic basis for this block has not been well explored.
We found that ribosome occupancy of specific transcripts,
such as CyclinD1, CyclinD2, CDK6 and CDK8, which
regulate cell cycle progression, is reduced by Silvestrol
treatment (Figure 3g; Table S2 in Additional file 2) and
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eIF4A inhibition. Notably, Cyclin E1 and Cyclin B1 pro-
duction was unaffected by Silvestrol, demonstrating that
loss of Cyclin D1 is specific and cannot be attributed to
the short half-life of the protein. Furthermore, Silvestrol-
like compounds induced apoptosis through Caspase 9
cleavage in LNCaP cells [36]. We found that Silvestrol
caused a significant loss of ribosomes on the BCL2 tran-
script and a loss of Bcl2 protein (Table S2 in Additional
file 2; Figure 3e,g; ΔTE = -7.04). Depletion of Bcl2 corre-
lated with an observed increase in sub-G1 cells (Figure 3c
bottom panels) and cleavage of PARP (Figure 3f), suggest-
ing that eIF4A mediates cell survival, at least in part, by
regulating BCL2 translation. Finally, a previous study
found that eIF4F inhibition impaired cell migration in
highly metastatic TM15 breast cancer cells [26]. Accord-
ingly, our work indicates that cell migration is regulated in
an eIF4A-dependent manner (Figure 3a; Additional file 6).
We show that Silvestrol strongly blocks ribosome assem-
bly on ARF6 (Table S2 in Additional file 2; ΔTE = -13.14),
a key regulator of migration, and causes loss of Arf6 pro-
tein (Figure S5d in Additional file 6). Indeed, silencing
ARF6 in MDA-MB-231 cells has been shown to impair
migration and invasion [27] and ARF6 overexpression in
conjunction with a partner, Gep100, triggered invasion in
non-invasive MCF-7 cells [28]. Our data indicate that
eIF4F mediates cell migration through eIF4A yet, taken
jointly with our cell survival results, the impact of eIF4A
inhibition on migration cannot be separated from the in-
duction of cell death. Since apoptosis becomes evident in
MDA-MB-231 cells 8 hours after exposure to Silvestrol
(Figure 3c,f ), measurements of cell migration taken
beyond 8 hours in compound should be interpreted
with caution. Nevertheless, the novel finding that
ARF6 translation relies on eIF4A activity highlights the
central role of this helicase in controlling metastatic
potential in MDA-MB-231 cells. Our findings illustrate
the impact of Silvestrol on cellular processes with pro-
oncogenic properties and highlight translation initiation
as a principal regulatory node in malignant progression.
Importantly, the helicase activity of eIF4A in vitro is
known to be strongly stimulated by its association with
other initiation factors, namely eIF4G, eIF4B and eIF4H
[37,38]. Thus, eIF4A requires interaction with partner
proteins for efficient activity. Our findings suggest that
abrogating eIF4A activity is not equivalent to interrupt-
ing the assembly of eIF4E and eIF4G, since inhibition of
both appears to be required to achieve a maximal block
to eIF4F function. If disrupting the integrity of eIF4E-eIF4G
interaction were equivalent to abolishing eIF4A activity,
we would not have expected the effects of Silvestrol and
mTOR inhibitors to be additive. Furthermore, the pool of
transcripts most dependent on eIF4A for translation is
distinct from those impacted by mTOR inhibition, whichabrogates eIF4E-eIF4G assembly. This holds true both in
the identity of genes which comprise each pool and in the
features that define their dependency. These observations
may be explained by one or more of the following possi-
bilities. First, different isoforms of the canonical eIF4F
complex may exist that have variable activity and/or dif-
ferential target transcripts. Indeed, eIF4G2, a homolog
of eIF4G, significantly impacts protein synthesis [39]
but does not bind eIF4E and is not required for translation
of 5′ TOP mRNAs [16,40]. Second, stimulation of eIF4A
activity could occur through an eIF4E-independent mech-
anism, thereby diminishing the requirement for eIF4E:
eIF4G assembly on certain transcripts. Third, eIF4E and
eIF4G may have the capacity to assemble and recruit
translation machinery in the absence of eIF4A. This would
suggest that eIF4A is only stringently required on tran-
scripts with long, structured 5′ termini and, possibly,
5′ UTR introns. Fourth, association of eIF4A in the
eIF4F complex may be sufficient for activation of
eIF4F-mediated translation even in the absence of heli-
case activity. In this scenario, the active helicase would
only be required when scanning initiation complexes
encounter structured regions in target transcripts. Alter-
natively, association of eIF4A with certain unstructured or
short 5′ UTRs, with or without associated factors, might
negatively impact translation. Under these circumstances,
blocking eIF4A activity would relieve inhibition and may
underlie the observation that a small subset of transcripts
exhibit increased TE when exposed to Silvestrol. These
intriguing possibilities warrant further dissection of the
interactions between initiation factors, their assembly
on target mRNAs and the role of mRNA elements in
mediating translation regulation within the cell. Such
studies will be required to fully understand the individ-
ual contributions of eIF4F components to translation
initiation.
Conclusions
Here we provide the first genome-wide profile of the
translational signature of eIF4A and show that this
helicase regulates the translation of specific mRNAs
involved in proliferation, survival and metastasis, con-
sistent with the notion that eIF4F acts at an important
node in tumorigenesis. We also find that the popula-
tion of eIF4A-dependent mRNAs is distinct from those
that depend on 4E-BP-mediated assembly of eIF4E and
eIF4G. In support of this notion we observed that cata-
lytic mTOR inhibitors, which block the assembly of
eIF4F, additively blocked cell proliferation when used
in combination with Silvestrol. These observations raise
the possibility that anti-cancer therapies aimed at blocking
translation would be more effective if multiple governing
factors were inhibited in combination. Additionally,
the effect of a single agent targeting the translation
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parallel pathway, thereby increasing the likelihood of
acquired resistance. We propose that eIF4F target mRNAs
have differential requirements for individual components
of the complex, and possibly other initiation factors,
that allow for dynamic regulation of their translation.
If this were true, alterations to the balance of each sub-
unit in eIF4F could uniquely influence malignant
transformation by impacting the translation of discrete
mRNA subsets. This could lead to altered proteomic
landscapes with signatures that differ depending on
which eIF4F component drives transformation. Genome-
wide dissection of the translational output of individual
eIF4F constituents and other initiation factors will be
critical for our understanding of malignant progression
and will guide future efforts aimed at targeting this
central hub in cancer signaling. Moreover, further ana-
lyses of cancer-specific translational profiles will likely
uncover novel biomarkers for malignant subtypes and




Cells were seeded at a density of 1 × 103 cells/well in
96-well plates and treated with Silvestrol at the following
final concentrations: 3, 1, 0.3, 0.1, 0.03, 0.01, and 0 μM.
Plates were incubated for 3 days and cell viability was
measured using CellTiter-Glo luminescent viability re-
agent (Promega, Sunnyvale, CA USA).
Metabolic labeling
MDA-MB-231 cells were seeded at a density of 3 × 105
cells/well in 6-well format and grown overnight. 24 hours
after seeding, cells were washed in 1× phosphate-
buffered saline (PBSand media was replaced with RPMI
lacking methionine; cells were incubated in the absence
of methionine for 1 hour. Methionine-free medium
containing Silvestrol was added to each well and cells
were pulsed with 0.1 mCi/ml 35S-methionine/cysteine
(EasyTag EXPRESS35S Protein Labeling Mix, Perkin
Elmer #NEG77200, Santa Clara, CA, USA) for 10 minutes
prior to harvest. Cells were lysed in RIPA buffer (50 mM
Tris-HCl pH7.5, 150 mM NaCl, 2 mM EDTA pH8,
1% TritonX-100, 1% sodium deoxycholate, 0.1% SDS)
containing complete EDTA-free protease inhibitors
(Roche #11836170001, Indianapolis, IN, USA), and
phosphatase inhibitors (PhosSTOP, Roche #04906837001).
Total protein was trichloroacetic acid (TCA precipitated
and the radioactive counts were measured by scintillation
counting. Protein content in cell lysates was quantified
using BCA reagent (Thermo Scientific #23228, Rockford,
IL, USA) and used to normalize radioactive counts in
TCA precipitated protein.Polysome analysis and fractionation
Cells were seeded at a density of 4 × 106 cells/plate in
15 cm plates and grown overnight. Cells were then
treated with DMSO or Silvestrol (25 nM) for 2 hours
prior to harvest. At time of harvest, 100 μg/ml cyclo-
heximide (Sigma-Aldrich, St. Louis, MO, USA) was
added to each plate and incubated for 1 minute. Cells
were washed twice in ice-cold 1× PBS +100 μg/ml
cycloheximide and lysed in ice-cold polysome lysis
buffer (12.5 mM Tris pH7, 7.5 mM Tris pH8, 15 mM
MgCl2, 200 mM NaCl, 1 mM DTT, 8% glycerol,
100 μg/ml cycloheximide, 24 U/ml Turbo DNase I
(Life Technologies #AM2238, Grand Island, NY,
USA), 1% TritonX-100 ). Sucrose gradients (10 to
50%) were created by layering 10% and 50% sucrose
solutions (15 mM Tris pH8, 100 mM KCl, 3 mM
MgCl2, 1 mM DTT, 100 μg/ml cycloheximide, 20 U/
ml Superase Inhibitor (Ambion #AM2696), 10 or 50%
RNase-free sucrose) into Seton tubes (Seton Scientific
#7030, Los Gatos, CA, USA) followed by mixing with
the BioComp Gradient maker set at an 81.5° angle at
16 rpm (BioComp Instruments, Fredericton, NB,
Canada). Lysates were layered on top of each gradient
and subjected to ultracentrifugation in an SW41-Ti
rotor at 35,000 rpm at 4°C for 3 hours. Polysome
profiles were analyzed using a BioComp Gradient Sta-
tion at constant speed with optical monitoring at a
260 nm wavelength. For polysome fractionation ex-
periments, 1 ml fractions were collected and stored at
-80°C for subsequent RNA isolation followed by
quantitative RT-PCR.Preparation of samples for ribosome profiling
Ribosome profiling was performed as previously
described [11,41] with some modifications. Briefly,
MDA-MB-231 cells were treated with Silvestrol (25 nM
for 1or 2 hours), DMSO (1:4,000 for 1 or 2 hours) or
INK128 (200 nM for 2 hours). After treatment cells
were washed twice in cold PBS containing
cycloheximide (100 μg/ml) and lysed in lysis buffer
(20 mM Tris pH7, 1% TritonX-100, 220 mM NaCl,
15 mM MgCl2, 1 mM DTT, 8% glycerol, 100 μg/ml
cycloheximide (Sigma), 24 U/ml Turbo DNAse
(Ambion)). Lysates were clarified, treated with RNAse I
(Ambion) and overlaid on a 34% sucrose cushion.
Monosomes were isolated by centrifugation at
69,000 rpm for 4 hours in a TLA110 rotor. Ribosome
protected RNA fragments (RFs) were isolated from
monosome fractions by acidic-phenol extraction and
used to generate libraries for sequencing. The genome-
aligned RF profiles in Additional file 3 represent the
count of bases occupying the ribosomal P-site, calcu-
lated by mapping the p-offset for sequencing reads.
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Total RNA was extracted from MDA-MB-231 cells
using Trizol (Life Technologies #15596026, Grand Island,
NY, USA) following the manufacturer’s guidelines. Polya-
denylated RNA was isolated from the total fraction using
Oligotex mRNA kit (Qiagen #70022, Germantown, MD,
USA). The resulting mRNA was partially fragmented by
alkaline hydrolysis with sodium carbonate to generate
approximately 150-nucleotide fragments on average. RNA
fragments of 40 to 100 nucleotides were isolated by gel
extraction and used to generate libraries for mRNA-Seq.
The genome-aligned mRNA profiles in Additional file 3
represent counts of the 5′-terminal bases of sequencing
reads.
Library generation and sequencing
Strand-specific libraries were generated as described
[11,41] with modifications described in Stern-Ginnosaur
et al. [13]. Samples were sequenced on the Illumina HiSeq
2000 using the TruSeq SBS Kit v3 50 cycles (Illumina
#FC-401-3002, San Diego, CA, USA), yielding single end
reads that were 50 base pairs in length.
Sequencing data analysis
Sequence analysis was performed as described [13].
Briefly, linker and polyA sequences were removed from
the 3′ end reads prior to alignment. Reads were then
aligned with Bowtie [42] with no more than two mis-
matches allowed end-to-end (-v2) and with reporting up
to 16 alignments (-a –m -16). Sequences aligning to
rRNA were discarded and the remaining reads were
aligned in parallel to the human genome (hg19) as well
as to UCSC KnownGene canonical transcripts [43].
These alignments were merged and uniquely mapped
reads were counted to calculate the mRNA and ribosome
footprint RPKM value. Genomic positions with non-
uniquely aligned reads as well as positions that overlapped
with more than one KnownGene canonical transcript
were excluded from the RPKM calculation. When com-
puting counts for mRNA-Seq data, the count was assigned
to the genomic position corresponding to the middle of
each read. For RF-Seq reads, counts were assigned to the
genomic location that corresponded to the 5′-most base
present in the P-site of the ribosome which protected the
mRNA fragment from RNase I digestion. The location of
the P-site in RF reads was calculated based on the mapped
distance from the 5′-terminal base to the base occupying
the P-site of the translating ribosome [11,13,41]. The
RPKM values per gene for mRNA-Seq and RF-Seq were
visualized using Spotfire Analytic software (TIBCO,
Boston, MA, USA). The genome-aligned RF profiles in
Additional file 3 represent the count of bases occupying
the ribosome P-site; corresponding mRNA profiles repre-
sent counts of the 5′ terminal bases of sequenced reads.5′ UTR analysis
5′ UTR sequences were retrieved from Ensemble using
RefSeq mRNA numbers as query. Folding energies of the
resulting sequences were analyzed using CONTRAfold [25]
and McCaskill [44] RNA structure prediction algorithms.
Reporter constructs
The CMV promoter was amplified by PCR and cloned
into the SacI restriction site of pGL4.25 to create vector
pGL4.25CMV. The promoter was subsequently mutagen-
ized at a single site to remove an internal NcoI site and
create vector pMH2. 5′ UTR sequences from CyclinD1
and ROCK1 were reverse transcribed from total RNA iso-
lated from MDA-MB-231 cells (SuperScript III, Invitrogen
#18080-051) and the resulting cDNA was amplified by
high-fidelity PCR using 5′ UTR-specific oligonucleotides.
The 5′ UTRs for ARF6, ARF6mut and PFN2 were synthe-
sized by Blue Heron Biotechnology (Bothell, WA, USA).
5′ UTRs were subcloned into the NcoI site of vector
pMH2 to create vectors pCR300, pCR301, pCR302,
pCR303, and pCR304 (Table S5 in Additional file 2).
Luciferase assays
293 T cells were co-transfected with 5′ UTR-bearing
luc2CP vectors plus pBabePuro at a ratio of 20:1. Medium
was replaced with DMEM +2 μg/ml puromycin 48 hours
post-transfection and cells were grown to select for
puromycin-resistant colonies. Stably transfected cells were
seeded in 96 well plates at 4 × 104 cells/well and allowed
to settle overnight. Medium was removed and replaced
with 100 μl/well of medium containing 0, 12.5, 25, 50, 100
or 200 nM Silvestrol or 0, 0.03125, 0.0625, 0.125, 0.25, 0.5,
1, 2, 4 μM hippuristanol and incubated for 40 minutes.
Silvestrol-containing medium was removed and cells were
lysed in 20 μl/well Passive Lysis Buffer (Promega E194A).
Luciferase assays were performed by adding 100 μl/well
Luciferase Assay Reagent (Promega E1501) and incubating
for 10 minutes at room temperature before measuring lu-
minescence. For luc2CP mRNA analysis, 4 × 105 cells/well
were seeded in 6-well plates and grown overnight. Cells
were then treated with the indicated amounts of Silvestrol
for 40 minutes and lysed using Trizol reagent. RNA was
isolated from Trizol lysates using standard methods. The
abundance of luc2CP and β-actin mRNA was subse-
quently analyzed by quantitative RT-PCR.
RNA isolation from polysome fractions
Prior to RNA extraction from polysome fractions, 5 ng
of Luciferase Control RNA (Promega) was added to each
fraction. Samples were treated with 200 μg/ml Proteinase
K for 1 hour at 50°C and RNA was extracted using the
standard hot acid phenol method. RNAs were precipitated
using isopropanol and resuspended in 10 mM Tris pH7.
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Total RNA was converted to cDNA using SuperScript III
reverse transcriptase (Invitrogen) with oligo dT primers
according to the manufacturer’s instructions. Transcript
levels were measured by quantitative PCR using SYBR
green FAST PCR mix (Applied Biosystems, Foster City,
CA) and oligo pairs specific to each transcript. In poly-
some fractionation experiments, transcript levels were
normalized to luciferase control RNA abundance. To
measure luciferase reporter mRNA (luc2CP mRNA)
levels, transcript abundance was normalized to β-actin
mRNA measurements.
Cell cycle assays
MDA-MB-231 cells were seeded in 6-well dishes at
3.5 × 105 cells/well and grown overnight. At the start of
the experiment, growth medium was replaced with
medium containing 25 nM Silvestrol. Cells were pulsed
with 1 μM BrDU for 30 minutes before harvesting by
trypsinization at the indicated time points. To measure
sub-G1 populations, medium was collected along with
adherent cells at time of harvest. BrDU-pulsed cells
were pelleted, washed in 1× PBS and fixed using ice-
cold 70% ethanol. Fixed cells were permeabilized on ice
in 1× PBS containing 0.1 M HCl and 0.5% Triton X-100,
washed and then boiled for 10 minutes. Cells were then
incubated with 5 μg/ml anti-BrDU-fluorescein isothio-
cyanate (FITC) antibody (BD Biosciences #347583, San
Jose, CA, USA) at room temperature for 30 minutes,
washed, resuspended in PI/RNase solution (BD Biosci-
ences #550825) and analyzed by fluorescence-activated
cell sorting (FACS).
Western blotting
MDA-MB-231 cells were treated with 25 nM Silvestrol
and lysed in RIPA buffer (50 mM Tris-HCl pH7.5,
150 mM NaCl, 2 mM EDTA pH8, 1% TritonX-100, 1%
sodium deoxycholate, 0.1% SDS) containing complete
EDTA-free protease inhibitors (Roche #11836170001), and
phosphatase inhibitors (PhosSTOP, Roche #04906837001).
Lysates were quantified using BCA reagent (Thermo
Scientific #23228). Lysates were subjected to SDS-PAGE
(NuPAGE) using 15 to 25 μg of cell lysate per well and
transferred to PVDF (Invitrogen).
Antibodies
The following antibodies were purchased from commer-
cial suppliers: CyclinD1 (Cell Signaling #2926, Beverly,
MA, USA), CyclinB1 (Cell Signaling #4135), CyclinE1
(Cell Signaling #4129), Bcl2 (BD Pharmingen #551097),
Parp(Asp214) (Cell Signaling #9541), Arf6 (Cell Signal-
ing #5740), GAPDH (Santa Cruz Biotechnology#32233,
Santa Cruz, CA, USA), β-Tubulin (Cell Signaling #2146).Cell lines
Cell lines used in this study were obtained from ATCC.
Cells were tested for mycoplasma by the Novartis Insti-
tutes for Biomedical Research and were mycoplasma-free.
Oligonucleotides
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Digestion of monosome pellets
Monosome preparations pelleted in ultracentrifuge tubes
were washed with 1 ml ice-cold ethanol by addition of
the ethanol followed by a 5 minute incubation on ice
and aspiration of the ethanol via a vacuum trap. The
pellet was allowed to air dry. Monosome pellet was dis-
solved in 100 μl of a solution of 20 mM ammonium bi-
carbonate, 8 M urea and 2 mM Tris(2-carboxyethyl)
phosphine hydrochloride. MS-Grade Lys C (Thermo)
was dissolved in water to a concentration of 0.5 μg/μl
and 2 μl was added to the dissolved pellet. The Lys C
digestion was incubated for 4 hours at room temperature.
The digestion was further diluted with an additional 98 μl
of water. MS-Grade Trypsin (Thermo) was also dissolved
in water to a concentration of 0.5 μg/μl and 2 μl was
added to the diluted Lys C digestion. This trypsin diges-
tion was incubated overnight at room temperature.
Microscale LC-MS/MS and mascot ions search of trypsin
digestion samples
Digestion samples were prepared for liquid chromatog-
raphy-tandem mass spectrometry (LC-MS/MS) by acidifi-
cation. The digestion sample (20 μl) was acidified by the
addition of 2 μl of 10% formic acid; 20 μl of this sample
was injected onto a 2.1 × 50 mm Extend-C18 column
(1.8 μm beads; Agilent, Santa Clara, CA, USA) at
400 μl/minute flow rate. Elution of peptides was over a
51 minute gradient from 5 to 40% acetonitrile with
0.1% formic acid as the modifier, and a flow rate of
200 μl/minute. Data acquisition was on an Agilent
6530 Q-ToF instrument equipped with a dual electro-
spray source, and a reference mass of 922.009798
enabled. MS/MS spectra were acquired in Auto MS/MS
mode with triggering of precursor ions of +2 charge state
and higher and individual ions were excluded for 9 seconds
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were selected per MS scan, and MS/MS scans were for
50,000 counts or 333 mS, whichever came first. LC-
MS/MS data were exported to a Mascot Generic Format
file using MassHunter Qual 5.0 (Agilent) and searched
against SwissProt 51.6 with taxonomy limited to human,
without modifications other than variable pyroglutamate
formation at Q and E, MS tolerance of 10 ppm and MS/
MS tolerance of 0.1 Da.
Nano LC-MS/MS and mascot ions search of trypsin digestion
samples
Digestion samples were prepared for LC-MS/MS by
acidification. The digestion sample (10 μl) was acidified
by the addition of 10 μl of 1% formic acid; 4 μl of this sam-
ple was injected onto a 4 mm 40 nL trap column at a flow
rate of 3 μl/minute and analyzed on a 75 μm× 150 mm
column containing Zorbax 300SB-C18 (5 μm beads) at a
flow rate of 400 nl/minute. Elution of peptides was over a
100 minute gradient from 5 to 40% acetonitrile with 0.1%
formic acid as the modifier. Data acquisition was on an
Agilent 6550 Q-ToF instrument equipped with the
ChipCube source, and a reference mass of 1221.990637
enabled. MS survey scans were acquired at a rate of 5 Hz,
and MS/MS spectra were acquired in Auto MS/MS mode
with triggering of precursor ions of +2 charge state and
higher. Individual ions were excluded for 18 seconds after
triggering an MS/MS scan. Up to five precursors were se-
lected per MS scan, and MS/MS scans were for 25,000
counts or 200 mS, whichever came first. LC-MS/MS data
were exported to a Mascot Generic Format file using
MassHunter Qual 5.0 and searched against SwissProt
51.6 with taxonomy limited to human, without modifi-
cations other than variable pyroglutamate formation at
Q and E, MS tolerance of 5 ppm and MS/MS tolerance
of 0.1 Da.
Sliding window analysis
5′ UTR sequences were retrieved from Ensemble using
RefSeq mRNA names as query. Sequences were broken
into 20-nucleotide fragments in a stepwise manner be-
ginning from the first nucleotide (n) and proceeding in 1
nucleotide steps (n +1, n +2, n +3, and so on) through
the length of the UTR. The structure of each fragment
was analyzed using the CONTRAfold algorithm and the
resulting free energy values were plotted based on their
position across the length of the UTR, as were the per-
centage GC values.
Trans-well migration assay
Migration assays were performed using trans-well migra-
tion chambers (BD Biosciences). MDA-MB-231 cells were
seeded into upper chambers at a density of 0.5 × 105 cells
in serum-free medium. Medium containing 5% fetalbovine serum was aliquoted to lower wells and cells were
incubated for 22 hours. When measuring migration in the
presence of Silvestrol, compound was included in the
medium in both upper and lower chambers at the con-
centrations indicated. To assess cell migration after
22 hours, upper chambers were transferred to wells
containing 1× PBS +8 μM Calcenein AM (Life Technolo-
gies) and incubated for 40 minutes. Fluorescence was eval-
uated by excitation at 485 nM wavelength followed by
measuring emission at 520 nM.
Scratch wound assay
Cells were seeded into 24 well plates at a density of
6 × 105 cells/well in RPMI supplemented with 10%
fetal bovine serum and grown for 24 hours to generate
a monolayer. The following day cells were scratched to
produce a wound in the monolayer and wound closure
was monitored by microscopy using the Incucyte Live Cell
Imaging system (Essen Biosciences, Ann Arbor, MI, USA).
Data availability
The next generation sequencing data presented in this
paper have been deposited in NCBI’s Gene Expression
Omnibus [45] and are accessible through GEO Series
accession number GSE61375 [46]. The mass spectrom-
etry data have been deposited to the ProteomeXchange
Consortium [47] via the PRIDE partner repository [48]
with the dataset identifier PXD001310 and DOI 10.6019/
PXD001310.
Additional files
Additional file 1: Figure S1. MDA-MB-231 polysome profiles in the
presence of translation inhibitors. MDA-MB-231 cells were treated with
DMSO, 25 nM Silvestrol or 1 μg/ml harringtonine for 30 minutes. Lysates
were fractionated by ultracentrifugation through a sucrose gradient and
polysome distribution was analyzed by monitoring absorbance of light at
260 nm (A260).
Additional file 2: Table S1. Mass spectrometry of monosome fractions
from MDA-MB-231 cells. LC-MS/MS mass spectrometry was performed using
monosome fractions from (a) DMSO- or (b) Silvestrol-treated MDA-MB-231
cells. Proteins were identified by Mascot using peptide sequences as query;
those with 98% confidence or greater are listed for each replicate sample.
Table S2: Genes showing reduced TE in Silvestrol. Table of 284 genes
identified by ribosome profiling as having reduced TE in the presence of 25
nM Silvestrol. Genes are organized based on fold change in TE (ΔTE) values.
Table S3: Genes showing increased TE in Silvestrol. Table of 146 genes
identified by ribosome profiling as having increased TE in the presence of
25 nM Silvestrol. Genes are organized based on fold change in TE (ΔTE)
values. Table S4: 5′ UTR characteristics of Silvestrol-sensitive and
-insensitive genes. Table showing free energy values (ΔG), length and
percentage GC content for 5′ UTRs from genes that are sensitive (decreased
ΔTE) or insensitive to 25 nM Silvestrol. ΔG values were predicted using two
algorithms, CONTRAfold or McCaskill [44]. The correlation coefficient for
these data sets is r =0.914. Genes bearing variant 5′ UTR isoforms are
indicated with an asterisk. Table S5: Table of vectors used in luciferase
reporter assays. Vector pMH2 was constructed from pGL4.25 with CMV
promoter in place of the minimal promoter. Vectors pCR300, pCR301,
pCR302, pCR303, and pCR304 were constructed by adding the indicated 5′
UTRs to vector pMH2. See Materials and methods for cloning information.
Rubio et al. Genome Biology 2014, 15:476 Page 17 of 19
http://genomebiology.com/2014/15/10/476Table S6: Genes showing reduced TE in INK128. Table of 244 genes that
showed reduced TE in MDA-MB-231 cells treated with 200 nM INK128 for
2 hours. The gene also found to have reduced TE after Silvestrol treatment
is indicated by asterisks.
Additional file 3: Figure S2. Select data from ribosome profiling
sequencing. (a) The frequency of read lengths from RNA-Seq libraries
generated by ribosome footprinting (RF). (b) Table of sequencing statistics
for sample generated by next-generation sequencing. Coverage was
computed using the Picard HsMetrics tool for every exon in the KnownGene
database. Exons with fewer than two reads were excluded. Abbreviations: br,
biological replicate; RF, ribosome footprint. (c) Scatter plot of RF densities
(measured in RPKM) in MDA-MB-231 cells treated with 25 nM Silvestrol versus
DMSO for 1 hour. Silvestrol-sensitive genes are indicated in dark blue.
Additional file 4: Figure S3. Polysome analysis of select Silvestrol-sensitive
transcripts. Polysomes from 25 nM Silvestrol- or DMSO-treated cells were
fractionated and analyzed for the abundance of transcripts for β-actin,
CyclinD1, ARF6, ROCK1, CDK6 and BCL2. Data presented are mean
values ± standard error (n =2).
Additional file 5: Figure S4. Structured 5′ UTRs from Silvestrol-sensitive
transcripts, used to evaluate 5′ UTR contribution to translation of a luciferase
reporter. (a) Free energy values for the 5′ UTRs of Silvestrol-sensitive genes;
genes are separated into three classes based on TE values: Decreased TE
(n =284), insensitive (n =299) and increased TE (n =146). Energy values
were predicted using the CONTRAfold algorithm. The pool of genes with
decreased TE values are enriched with structured 5′ UTRs. (b) Luciferase
production from CMV-driven luc2CP (pMH2) in the presence of cycloheximide
(100 μg/ml) or Silvestrol (50 nM) over time. Half-life of Luc2CP protein is
30.99 minutes. In each experiment, samples were assayed in triplicate; data
were derived from two independent experiments. (c-e) Plots of sequencing
data derived from genes selected for 5′ UTR assessment. Data represent the
non-normalized frequency of either the 5′end (mRNA) or P-site (RF) of each
read found in sequencing data. (f) Luc2CP mRNA levels in Silvestrol-treated
293 T cells bearing the indicated reporter constructs. Luc2CP abundance was
measured by quantitative PCR and normalized to β-actin mRNA levels. Data
represent mean values ± standard error of the mean (n =3).
Additional file 6: Figure S5. Luciferase expression from 5′ UTR reporter
constructs upon treatment with hippuristanol. (a) Luciferase reporter
constructs, stably transfected into 293 T cells, were treated with increasing
concentrations of hippuristanol and luciferase expression was measured
after 40 minutes; constructs bearing 5′ UTRs from Silvestrol-sensitive genes
(CyclinD1, ROCK1, ARF6) or insensitive genes (PFN2 or CMV alone) were
compared. (b) Luciferase expression from reporter constructs bearing
ARF6wt 5′ UTR or ARF6mut 5′ UTR, stably transfected into 293 T cells. Cells
were treated with increasing concentrations of hippuristanol and
measurements were taken after 40 minutes of exposure. Data
presented were obtained from two independent experiments with
measurements taken in triplicate.
Additional file 7: Figure S6. Sliding window structure analysis of select
5′ UTRs. (a,b) Free energy values (a) and percentage GC content (b) of
20-nucleotide fragments of the 5′ UTR of CyclinD1 plotted along the
length of the UTR from the TSS to the translation start (AUG). (c-f) Free
energy values (c,e) and percentage GC content (d,f) of the 5′ UTR of ARF6
(c,d) and ARF6mut (e,f) plotted along the length of the UTR from the TSS
to the translation start (AUG). Each asterisk denotes a structured region
that was mutated in ARF6 to create ARF6mut.
Additional file 8: Figure S7. Silvestrol treatment impairs migration of
MDA-MB-231 cells. (a) Migration of MDA-MB-231 cells was measured in a
trans-well migration assay in the presence of increasing amounts of Silvestrol.
Plots represent Calcenein AM fluorescence of cells which migrated across a
barrier. (b) MDA-MB-231 cells were grown to a confluent monolayer and
scratched to produce a wound. Wound closure was monitored over time by
microscopy. (c) Quantification of wound closure (represented in (b)) over time.
(d) Western blot for Arf6 protein after treatment with 25 nM Silvestrol.
Additional file 9: Figure S8. Translation of Silvestrol-sensitive transcripts is
not disrupted by mTOR inhibition. (a) MDA-MB-231 cells were treated with
vehicle (DMSO) or 200 nM INK128 for the indicated times and Western blots
were performed for Arf6 (top panels) and Cyclin D1 (bottom panels). (b) PC-3
cells were treated with vehicle (DMSO), 200 nM INK128 or 25 nM Silvestrol forthe indicated times. Western blots were performed for Arf6, Cyclin D1 and
phosphorylated 4E-BP1/2 (Ser65).
Additional file 10: Figure S9. Combinatorial treatment with Silvestrol
and mTOR inhibitors show additivity in blocking cancer cell proliferation.
(a,b) Isobolograms (top panels) and dose matrices (bottom panels) of
MDA-MB-231 (a) and PC-3 (b) cells treated with serial combinations of
Silvestrol and INK128. (c,d) MDA-MB-231 (c) or PC-3 (d) cells were treated
with increasing concentrations of Silvestrol in combination with PP242 at
fixed doses: 50 nM, 125 nM and 250 nM. Cell viability was measured by
CellTiter-Glo after 3 days. (e,f) Isobolograms (top panels) and dose matrices
(bottom panels) of MDA-MB-231 (e) and PC-3 (f) cells treated with serial
combinations of Silvestrol and PP242.
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